PDCD1 and vasculitis: Herein, we report three mesothelioma patients with mononeuritis multiplex, including two with pathology-proven vasculitis, following a recently approved combined anti-PD-1 (nivolumab)/anti-CTLA-4 (ipilimumab) first-line treatment (4).